Cognition Therapeutics Inc
NASDAQ:CGTX
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.239
3.18
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| US |
|
Cognition Therapeutics Inc
NASDAQ:CGTX
|
108.6m USD |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
972.2B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.5B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
277.1B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
209.4B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
219B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
272.1B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.7T DKK |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
148.3B USD |
Loading...
|
|
| FR |
|
Sanofi SA
PAR:SAN
|
93.8B EUR |
Loading...
|
Market Distribution
Other Profitability Ratios
Cognition Therapeutics Inc
Glance View
Cognition Therapeutics, Inc. is a clinical stage neuroscience company. The company is headquartered in Pittsburgh, Pennsylvania and currently employs 19 full-time employees. The company went IPO on 2021-10-08. The firm is engaged in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. The company is focused on developing a pipeline of small molecule product candidates that targets the sigma-2 receptor (S2R) complex, a key regulator of the cellular damage response for diseases such as Alzheimer’s disease (AD), dry age-related macular degeneration (dry AMD), geographic atrophy (GA), and other conditions. Its lead product candidate, CT1812, an orally delivered, small molecule antagonist designed to penetrate the blood-brain and blood-retina barriers to the S2R complex, and through its modulation restores normal function of synapses, as well as critical cellular processes, such as autophagy, cholesterol biosynthesis, vesicle trafficking, progesterone signaling and receptor stabilization at the cell surface.